1. Scrip
  2. >>Digital Technologies
  3. >>AI

Novartis’ Srinivasan On Putting Data Analytics To Use In Clinical Development

 
• By Anju Ghangurde

Badhri Srinivasan, head of global development operations at Novartis, outlines in an interview with Scrip the company’s efforts towards making clinical trials more efficient and decentralized, and how the Nerve Live data analytics platform is helping minimize non-performing sites.

Badhri Srinivasan
NOVARTIS' HEAD, GLOBAL DEVELOPMENT OPERATIONS, BADHRI SRINIVASAN

Novartis AG is working on multiple fronts to improve the efficiency of clinical trials and reduce the burden of participation in such studies for patients. The Swiss multinational is using a range of partnerships across the health and technology ecosystems to drive some of its efforts in the area.

In an interview with Scrip, Badhri Srinivasan, head of global development operations at Novartis, outlined how alliances such as that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

More from Digital Technologies

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.